ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 117 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.30 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $39,000 | -7.1% | 7,478 | +67.2% | 0.00% | – |
| Q2 2023 | $42,000 | +13.5% | 4,472 | +33.3% | 0.00% | – |
| Q1 2023 | $37,000 | -61.5% | 3,354 | -48.2% | 0.00% | – |
| Q4 2022 | $96,000 | +357.1% | 6,478 | +473.8% | 0.00% | – |
| Q3 2022 | $21,000 | +50.0% | 1,129 | +73.2% | 0.00% | – |
| Q2 2022 | $14,000 | -62.2% | 652 | -65.7% | 0.00% | – |
| Q1 2022 | $37,000 | -65.1% | 1,900 | -62.8% | 0.00% | – |
| Q4 2021 | $106,000 | +68.3% | 5,107 | +93.4% | 0.00% | – |
| Q3 2021 | $63,000 | +12.5% | 2,640 | +28.6% | 0.00% | – |
| Q2 2021 | $56,000 | +51.4% | 2,053 | +59.8% | 0.00% | – |
| Q1 2021 | $37,000 | +311.1% | 1,285 | +297.8% | 0.00% | – |
| Q4 2020 | $9,000 | +800.0% | 323 | +1600.0% | 0.00% | – |
| Q3 2020 | $1,000 | 0.0% | 19 | +11.8% | 0.00% | – |
| Q2 2020 | $1,000 | -93.8% | 17 | -96.9% | 0.00% | – |
| Q1 2020 | $16,000 | – | 557 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |